In this episode, Samuel J. Peretsman, MD, describes his background and experience with HIFU as a treatment for patients with prostate cancer, and also discusses his treatment criteria for the modality.
Be sure to listen our first episode as well:
Speaking of Urology podcast: Dr. Angela Smith discusses Jelmyto for low-grade UTUC
Cell-cycle risk score is predictive of ADT benefit in prostate cancer
May 17th 2024"Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk of death is for a man on surveillance," says Jonathan D. Tward, MD, PhD.